Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Turning Point Therapeutics Seeks $100 Million in IPO

Cancer drugmaker Turning Point Therapeutics recently filed paperwork calling for a $100 million initial public offering.

New CEO Appointed at Epic Sciences

Lloyd Sanders, previously with Myriad Genetics, has joined Epic Sciences as CEO.

Cellular Treatments for Diabetes Get $80M

BIOTECH: ViaCyte Built Up IP, Absorbed Rivals

In 1998, researchers derived stem cells from human embryos for the first time. With the advance came the hope of curing Type 1 diabetes.

Tease photo

San Diego Co. Sees Increasing Demand for CBD Products

CV Sciences is cashing in on rising demand for cannabidiol, or CBD.

Tease photo

PhaseBio Stock Jumps Following Good Results in Early-Stage Clinical Trials

PHARMA: Drug Used to Reverse Antiplatelet Activity

PhaseBio’s stock jumped March 18 after the company’s lead drug candidate showed promise in an early-stage clinical study.

Tease photo

Sharp HealthCare Wins Hearst Prize for Palliative Care Program

A Sharp HealthCare program that delivers palliative care at home captured the 2019 Hearst Prize.

CureMetrix’s Mammogram Software Wins FDA Approval

CureMetrix got the U.S. Food and Drug Administration’s blessing to market software that flags which mammograms raise suspicions of breast cancer.

PhaseBio Shares Rise on Clinical Study Data

PhaseBio’s stock jumped March 18 after the San Diego-based company’s lead drug candidate showed promise in an early-stage clinical study.

Life Sciences Leasing Activity Finished Strong in Q4 of 2018

For San Diego life sciences the fourth quarter of 2018 was the strongest of the year from a leasing perspective.

Tease photo

Potential Blockbuster Drug Could Bring Windfall to Scripps

Scripps Research stands to gain a royalty windfall from a drug candidate that slows brain atrophy in patients with multiple sclerosis.

Tease photo

More stories >>